FLT3 and acute myeloid leukemia: FLT3 mutations are present in approximately 30% of all patients with AML, with internal tandem duplication (ITD) accounting for approximately 25% of all AML cases and FLT3 mutation in the tyrosine kinase domain (FLT3-TKD) accounting for approximately 7–10% of all cases.